​

BioVie (BIVI) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BIVI Stock Rating

BioVie stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

BIVI Price Target Upside V Benchmarks

TypeNameUpside
StockBioVie-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.52$1.52$1.52
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-1---1
Nov, 25-1---1
Oct, 25-1---1
Sep, 25-1---1
Aug, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 01, 2024ThinkEquityBuyinitialise

Financial Forecast

EPS Forecast

$-100 $-70 $-40 $-10 $20 $50 Jun 24 Jun 25 Jun 26 Jun 27
Jun 24Jun 25Jun 26Jun 27
Reported$-73.00---
Avg Forecast$-10.10$-4.41$-6.00$43.30
High Forecast$-10.10$-4.41$-6.00$43.30
Low Forecast$-10.10$-4.41$-6.00$43.30
Surprise %622.77%---

Revenue Forecast

$-50M $40M $130M $220M $310M $400M Jun 24 Jun 25 Jun 26 Jun 27
Jun 24Jun 25Jun 26Jun 27
Reported----
Avg Forecast$-600.00K$-600.00K$12.80M$367.51M
High Forecast$-600.00K$-600.00K$12.80M$367.51M
Low Forecast$-600.00K$-600.00K$12.80M$367.51M
Surprise %----

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Jun 24 Jun 25 Jun 26 Jun 27
Jun 24Jun 25Jun 26Jun 27
Reported$-32.12M---
Avg Forecast$-45.64M$-19.93M$-27.11M$195.65M
High Forecast$-45.64M$-19.93M$-27.11M$195.65M
Low Forecast$-45.64M$-19.93M$-27.11M$195.65M
Surprise %-29.62%---

BIVI Forecast FAQ

Is BioVie stock a buy?

BioVie stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioVie is a favorable investment for most analysts.

What is BioVie's price target?

BioVie's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.52.

How does BioVie stock forecast compare to its benchmarks?

BioVie's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioVie over the past three months?

  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is BioVie’s EPS forecast?

BioVie's average annual EPS forecast for its fiscal year ending in June 2025 is $-4.41, marking a -93.96% decrease from the reported $-73 in 2024. Estimates for the following years are $-6 in 2026, and $43.3 in 2027.

What is BioVie’s revenue forecast?

BioVie's average annual revenue forecast for its fiscal year ending in June 2025 is $-600K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $12.8M, and $367.51M for 2027.

What is BioVie’s net income forecast?

BioVie's net income forecast for the fiscal year ending in June 2025 stands at $-19.927M, representing a -37.96% decrease from the reported $-32.121M in 2024. Projections indicate $-27.111M in 2026, and $195.65M in 2027.